
Silvano Cella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/901722/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effects of an acute bout of exercise on circulating extracellular vesicles: tissue-, sex-, and BMI-related differences. International Journal of Obesity, 2020, 44, 1108-1118.	3.4	60
2	The 5-HT1A receptor antagonist WAY 100635 improves rats performance in different models of amnesia evaluated by the object recognition task. Brain Research, 2003, 983, 215-222.	2.2	58
3	Children with Prader–Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children. European Journal of Endocrinology, 2010, 162, 499-505.	3.7	56
4	The nitric oxide donor molsidomine antagonizes age-related memory deficits in the rat. Neurobiology of Aging, 2005, 26, 259-264.	3.1	49
5	Effect of agonists and antagonists of cholinergic neurotransmission on growth hormone release in the dog. European Journal of Endocrinology, 1983, 103, 15-20.	3.7	47
6	The GABAB receptor and recognition memory: possible modulation of its behavioral effects by the nitrergic system. Neuroscience, 2003, 118, 1121-1127.	2.3	47
7	Effects of the nitric oxide donor molsidomine on different memory components as assessed in the object-recognition task in the rat. Psychopharmacology, 2002, 162, 239-245.	3.1	40
8	Anticipatory and consummatory effects of (hedonic) chocolate intake are associated with increased circulating levels of the orexigenic peptide ghrelin and endocannabinoids in obese adults. Food and Nutrition Research, 2015, 59, 29678.	2.6	36
9	Growth Hormone-Releasing Hexapeptide Is a Potent Stimulator of Growth Hormone Gene Expression and Release in the Growth Hormone—Releasing Hormone—Deprived Infant Rat. Pediatric Research, 1994, 36, 169-174.	2.3	35
10	Growth hormone abuse: methods of detection. Trends in Endocrinology and Metabolism, 2005, 16, 160-166.	7.1	32
11	Acute administration of capsaicin increases resting energy expenditure in young obese subjects without affecting energy intake, appetite, and circulating levels of orexigenic/anorexigenic peptides. Nutrition Research, 2018, 52, 71-79.	2.9	32
12	Prolonged fasting or clonidine can restore the defective growth hormone secretion in old dogs. European Journal of Endocrinology, 1989, 121, 177-184.	3.7	31
13	Menopausal transition: A possible risk factor for brain pathologic events. Neurobiology of Aging, 2009, 30, 71-80.	3.1	31
14	Synergistic effect of growth hormone-releasing hormone (GHRH) and clonidine in stimulating GH release in young and old dogs. Brain Research, 1990, 537, 359-362.	2.2	30
15	Synthetic hpGRF 1–40 stimulates growth hormone and inhibits prolactin secretion in normal children and children with isolated growth hormone deficiency. Peptides, 1983, 4, 929-933.	2.4	29
16	Somatostatin Withdrawal as Generator of Pulsatile GH Release in the Dog: A Possible Tool to Evaluate the Endogenous GHRH Tone?. Neuroendocrinology, 1996, 63, 481-488.	2.5	27
17	Augmentation of Growth Hormone Secretion in Children With Constitutional Growth Delay by Short Term Clonidine Administration: A Pulse Amplitude-Modulated Phenomenon*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 426-430.	3.6	26
18	Hexarelin, a potent GHRP analogue: Interactions with GHRH and clonidine in young and aged dogs. Peptides, 1995, 16, 81-86.	2.4	26

#	Article	IF	CITATIONS
19	α2-Adrenergic stimulation enhances growth hormone secretion in the dog: A presynaptic mechanism?. Life Sciences, 1983, 32, 2785-2792.	4.3	25
20	COVID-19 vaccine hesitancy among undocumented migrants during the early phase of the vaccination campaign: a multicentric cross-sectional study. BMJ Open, 2022, 12, e056591.	1.9	25
21	GH-related and extra-endocrine actions of GH secretagogues in aging. Neurobiology of Aging, 2002, 23, 907-919.	3.1	24
22	Combined evaluation of resting IGFâ€i, Nâ€terminal propeptide of type III procollagen (PIIINP) and Câ€terminal crossâ€inked telopeptide of type I collagen (ICTP) levels might be useful for detecting inappropriate GH administration in athletes: a preliminary report. Clinical Endocrinology, 2004, 61, 487-493.	2.4	24
23	Presynaptic α2-adrenergic stimulation leads to growth hormone release in the dog. Life Sciences, 1984, 34, 447-454.	4.3	23
24	Growth hormone-releasing hormone and clonidine stimulate biosynthesis of growth hormone in neonatal pituitaries. Biochemical and Biophysical Research Communications, 1986, 138, 1223-1230.	2.1	23
25	Studies of Growth Hormone Secretion in Calorically Restricted Dogs: Effect of Cholinergic Agonists and Antagonists, Glucose and Thyrotropin-Releasing Hormone. Neuroendocrinology, 1991, 53, 467-472.	2.5	23
26	A Child with Phenotypic Laron Dwarfism and Normal Somatomedin Levels. New England Journal of Medicine, 1989, 320, 376-379.	27.0	22
27	Combined Administration of Growth-Hormone-Releasing Hormone and Clonidine Restores Defective Growth Hormone Secretion in Old Dogs. Neuroendocrinology, 1993, 57, 432-438.	2.5	21
28	The leukocyte expression of CD36 is low in patients with Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 2007, 28, 515-518.	3.1	21
29	The burden of chronic noncommunicable diseases in undocumented migrants: a 1-year survey of drugs dispensation by a non–governmental organization in Italy. Public Health, 2016, 141, 26-31.	2.9	21
30	Whey Proteins Reduce Appetite, Stimulate Anorexigenic Gastrointestinal Peptides and Improve Glucometabolic Homeostasis in Young Obese Women. Nutrients, 2019, 11, 247.	4.1	21
31	Age-dependent modulation by galanin of growth hormone release from rat pituitary cells in culture. Life Sciences, 1990, 47, 1861-1866.	4.3	19
32	Molsidomine antagonizes L-NAME-induced acquisition deficits in a recognition memory task in the rat. Pharmacological Research, 2003, 47, 311-315.	7.1	19
33	Pilot Study of the Efficacy and Safety of a Modified-Release Magnesium 250mg Tablet (Sincromag??) for the Treatment of Premenstrual Syndrome. Clinical Drug Investigation, 2007, 27, 51-58.	2.2	19
34	Impact of a Three-Week in-Hospital Multidisciplinary Body Weight Reduction Program on Body Composition, Muscle Performance and Fatigue in a Pediatric Obese Population with or without Metabolic Syndrome. Nutrients, 2020, 12, 208.	4.1	19
35	Ontogeny of Growth Hormone-Releasing Factor in the Rat Hypothalamus. Neuroendocrinology, 1986, 44, 59-64.	2.5	18
36	Function of the GH/IGF-1 Axis in Healthy Middle-Aged Male Runners. Neuroendocrinology, 1996, 63, 498-503.	2.5	18

#	Article	IF	CITATIONS
37	Somatostatin Infusion Withdrawal: Studies in Normal Children and in Children with Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4426-4430.	3.6	18
38	Contrasting effects of nitric oxide on food intake and GH secretion stimulated by a GH-releasing peptide. European Journal of Endocrinology, 2001, 144, 155-162.	3.7	18
39	The Appetiteâ^`Suppressant and GLP-1-Stimulating Effects of Whey Proteins in Obese Subjects are Associated with Increased Circulating Levels of Specific Amino Acids. Nutrients, 2020, 12, 775.	4.1	18
40	Effect of somatostatin infusion on peptide YY secretion: studies in the acute and recovery phase of anorexia nervosa and in obesity. European Journal of Endocrinology, 2011, 165, 421-427.	3.7	16
41	Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases. Pulmonary Pharmacology and Therapeutics, 2018, 53, 80-85.	2.6	16
42	Effects of a 3-Week In-Hospital Body Weight Reduction Program on Cardiovascular Risk Factors, Muscle Performance, and Fatigue: A Retrospective Study in a Population of Obese Adults with or without Metabolic Syndrome. Nutrients, 2020, 12, 1495.	4.1	16
43	The Effects of Galanin on Growth Hormone Secretion in Children of Normal and Short Stature1. Pediatric Research, 1989, 26, 316-319.	2.3	15
44	Long-Term Failure of Compensatory Growth in Rats following Acute Neonatal Passive Immunization against Growth Hormone-Releasing Hormone. Neuroendocrinology, 1992, 56, 509-515.	2.5	15
45	Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine. Journal of Endocrinology, 1998, 156, 341-348.	2.6	15
46	The non-NMDA receptor antagonist NBQX does not affect rats performance in the object recognition task. Pharmacological Research, 2002, 45, 43-46.	7.1	15
47	Growth hormone (GH) rebound rise following somatostatin infusion withdrawal: studies in dogs with the use of GH-releasing hormone and a GH-releasing peptide. European Journal of Endocrinology, 2001, 145, 635-644.	3.7	14
48	Somatotropic Dysfunction in Growth Hormone-Releasing Hormone-Deprived Neonatal Rats: Effect of Growth Hormone Replacement Therapy. Pediatric Research, 1994, 36, 315-322.	2.3	13
49	GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide. Journal of Endocrinology, 2002, 174, 387-394.	2.6	13
50	Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin. European Journal of Endocrinology, 1999, 141, 313-320.	3.7	12
51	Multidisciplinary Integrated Metabolic Rehabilitation in Elderly Obese Patients: Effects on Cardiovascular Risk Factors, Fatigue and Muscle Performance. Nutrients, 2019, 11, 1240.	4.1	12
52	The Role of Aspartate Transaminase to Platelet Ratio Index (APRI) for the Prediction of Non-Alcoholic Fatty Liver Disease (NAFLD) in Severely Obese Children and Adolescents. Metabolites, 2022, 12, 155.	2.9	11
53	Neuroendocrine aging: Its impact on somatotrophic function. Neurochemistry International, 1994, 25, 5-10.	3.8	10
54	Unexpected Activation of Pituitary-Adrenal Axis in Healthy Young and Elderly Subjects during Somatostatin Infusion. Neuroendocrinology, 1998, 68, 123-128.	2.5	10

#	Article	IF	CITATIONS
55	Somatostatin infusion withdrawal: studies in the acute and recovery phase of anorexia nervosa, and in obesity. European Journal of Endocrinology, 2003, 148, 237-243.	3.7	10
56	Undocumented migrants during the Covid-19 pandemic: social conditions, clinical features and pharmacological treatment. Journal of Public Health Research, 2020, 9, 1852.	1.2	10
57	Neuroendocrine Control of Growth Hormone Secretion. Acta Paediatrica, International Journal of Paediatrics, 1989, 78, 87-92.	1.5	9
58	Down-regulation of α2-adrenoceptors involved in growth hormone control in the hypothalamus of infant rats receiving short-term clonidine administration. Developmental Brain Research, 1990, 53, 151-156.	1.7	9
59	Different Effects of Cholestyramine on Postprandial Secretions of Cholecystokinin and Peptide YY in Women with Bulimia Nervosa. Neuropsychobiology, 2014, 70, 228-234.	1.9	9
60	Nitric oxide modulation of the growth hormone—releasing activity of hexarelin in young and old dogs. Metabolism: Clinical and Experimental, 1999, 48, 176-182.	3.4	8
61	Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes. European Journal of Endocrinology, 2009, 160, 753-758.	3.7	8
62	Increased Tumor Cell Multiplication after Radiofrequency Lesions in Median Hypothalamus in the Mouse and Rat. Neuroendocrinology, 1986, 42, 407-415.	2.5	7
63	Abuse of Recombinant Human Growth Hormone: Studies in Two Different Dog Models. Neuroendocrinology, 2004, 79, 237-246.	2.5	6
64	Autonomous /3-endorphin secretion from the pituitary neurointermediate lobe: in vivo studies. Life Sciences, 1984, 34, 1605-1611.	4.3	5
65	Effect of cerebral hemisphere decortication on the cytotoxic activity of natural killer and natural cytotoxic lymphocytes in the mouse. Brain Research, 1990, 524, 297-302.	2.2	5
66	Testosterone Inhibition of Growth Hormone Release Stimulated by a Growth Hormone Secretagogue. Neuroendocrinology, 2006, 84, 115-122.	2.5	5
67	Psychotropic drugs prescription in undocumented migrants and indigent natives in Italy. International Clinical Psychopharmacology, 2017, 32, 294-297.	1.7	5
68	Frequent Medical Supervision Increases the Effectiveness of a Longitudinal Multidisciplinary Body Weight Reduction Program: A Real-World Experience in a Population of Children and Adolescents with Obesity. Nutrients, 2021, 13, 3362.	4.1	5
69	Effect of a somatostatin infusion on circulating levels of adipokines in obese women. Metabolism: Clinical and Experimental, 2012, 61, 1797-1802.	3.4	4
70	Evaluation of an Amino Acid Mix on the Secretion of Gastrointestinal Peptides, Glucometabolic Homeostasis, and Appetite in Obese Adolescents Administered with a Fixed-Dose or ad Libitum Meal. Journal of Clinical Medicine, 2020, 9, 3054.	2.4	4
71	Risk factors, awareness of disease and use of medications in a deprived population: differences between indigent natives and undocumented migrants in Italy. Journal of Public Health, 2021, 43, 302-307.	1.8	4
72	The Age-Dependent Increase of Metabolic Syndrome Requires More Extensive and Aggressive Non-Pharmacological and Pharmacological Interventions: A Cross-Sectional Study in an Italian Cohort of Obese Women. International Journal of Endocrinology, 2021, 2021, 1-10.	1.5	4

#	Article	IF	CITATIONS
73	Growth hormone releasing effect of hpGRF-40 in rats at different time intervals following ablation of the mediobasal hypothalamus. Life Sciences, 1984, 35, 1989-1995.	4.3	3
74	Eptastigmine augments basal and GHRH-stimulated growth hormone release in young and old dogs. Life Sciences, 1993, 53, 389-395.	4.3	3
75	GHRH plus arginine and arginine administration evokes the same ratio of GH isoforms levels in young patients with Prader-Willi syndrome. Growth Hormone and IGF Research, 2018, 39, 13-18.	1.1	3
76	Gender and age related differences in the use of medicines for chronic diseases among undocumented migrants. International Journal of Migration, Health and Social Care, 2018, 14, 221-229.	0.5	3
77	Will undocumented migrants contribute to change epidemiology, presentation and pharmacologic treatment of diabetes in Western countries?. Primary Care Diabetes, 2020, 14, 21-28.	1.8	3
78	Pharmacoepidemiological data from drug dispensing charities as a measure of health patterns in a population not assisted by the Italian National Health Service. Journal of Public Health Research, 2016, 5, 623.	1.2	2
79	Functional Interrelationships Between Adrenergic and Opioid Systems in the Neuroregulation of Growth Hormone Secretion in Infant Rats. Journal of Neuroendocrinology, 1991, 3, 357-361.	2.6	1
80	Effect of Enhancement of Cholinergic Tone on the Growth Hormone Response to Acute Hyperglycaemia or Thyrotropin-Releasing Hormone in Dogs. Journal of Neuroendocrinology, 1992, 4, 63-66.	2.6	1
81	A Syndrome of Phenotypic Laron-Type Dwarfism with Normal Levels of Insulin-like Growth Factor I. Acta Paediatrica, International Journal of Paediatrics, 1989, 78, 142-142.	1.5	0
82	Health needs assessment in patients assisted by a pharmaceutical non-profit charitable organisation: a preliminary pharmacoepidemiological survey based on the analysis of drug dispensation within Italy's Banco Farmaceutico. Italian Journal of Medicine, 2013, 9, .	0.3	0
83	Drugs Delivery by Charities: A Possible Epidemiologic Indicator in Children of Undocumented Migrants. Journal of Immigrant and Minority Health, 2017, 19, 1379-1385.	1.6	0
84	Multi-centric assessment of COVID-19 immunization access and demand among undocumented migrants. European Journal of Public Health, 2021, 31, .	0.3	0
85	Ethnic, clinical, and pharmacological predictors of high social dependence in COVID-19 patients admitted to post-acute care. Journal of Public Health Research, 2022, 11, 227990362211041.	1.2	0